Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

Lisan A Neefjes1, Gert-Jan R Ten Kate, Rossi Alexia

  • 1Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands. l.neefjes@erasmusmc.nl

Atherosclerosis
|October 25, 2011
PubMed

Insights

Familial hypercholesterolemia (FH) patients show accelerated coronary artery disease (CAD) development. Computed tomography coronary angiography (CTCA) reveals plaque extent and severity, influenced by gender and cholesterol levels.

Area of Science:

  • Cardiovascular imaging
  • Atherosclerosis research
  • Genetic lipid disorders

Background:

  • Familial hypercholesterolemia (FH) accelerates coronary artery disease (CAD) progression.
  • Early identification of CAD in FH is crucial for intervention.
  • Non-invasive CT coronary angiography (CTCA) assesses coronary plaque burden.

Purpose of the Study:

  • To determine the extent, severity, distribution, and type of coronary plaques in asymptomatic FH patients.
  • To utilize computed tomography (CT) for comprehensive plaque assessment.
  • To correlate plaque characteristics with patient demographics and lipid levels.

Main Methods:

  • 140 asymptomatic FH patients (statin-treated) underwent CT calcium scoring and CTCA.
  • Plaque characteristics evaluated: extent, severity (>50% lumen reduction), distribution, and type (calcified, non-calcified, mixed).
  • Clinical follow-up of 29 months assessed cardiac events.

Main Results:

  • 21% of patients had a calcium score of 0; 16% showed no CAD evidence.
  • 24% of patients had obstructive CAD; 11% of 775 detected plaques were obstructive.
  • Plaque extent correlated with gender, HDL, and LDL cholesterol levels.

Conclusions:

  • CAD development is accelerated in treated FH patients, regardless of gender.
  • Plaque burden varies significantly, with some patients having no plaque and others extensive obstructive CAD.
  • Gender and cholesterol levels are key determinants of CAD extent in FH.
Abstract

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Inflammation01:38

Inflammation

Overview